NasdaqGS - Nasdaq Real Time Price USD

Geron Corporation (GERN)

3.7925

+0.0625

(+1.68%)

As of 10:33 AM EDT. Market Open.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., April 18, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Business Wire 4 days ago

GERN
+1.68%
GERNW
Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future

We feel now is a pretty good time to analyse Geron Corporation's ( NASDAQ:GERN ) business as it appears the company may...

Simply Wall St. 12 days ago

GERN
+1.68%
GERNW
Geron to Participate at Upcoming Investor Conferences in April

FOSTER CITY, Calif., April 03, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following virtual investor conferences:

Business Wire 19 days ago

GERN
+1.68%
GERNW
5 FDA decisions to watch in the second quarter

The FDA could soon expand use of two multiple myeloma cell therapies as well as a top-selling medicine from Sanofi and Regeneron, while Pfizer’s years of gene therapy work might finally pay dividends.

BioPharma Dive 22 days ago

PFE

002722.SZ

MRNA
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.

Zacks last month

002722.SZ

CRNX

PTCT
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

FOSTER CITY, Calif., March 19, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,998 shares of its common stock at a price of $3.00 per share and pre-funded warrants to purchase 8,002,668 shares of its common stock. The pre-funded warrants are being sold at a price of $2.999 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. The offering included

Business Wire last month

GERN
+1.68%
GERNW
Geron, Madrigal Pharmaceuticals jump on good news from FDA

Shares of both Geron (GERN) and Madrigal Pharmaceuticals (MDGL) are soaring after receiving positive news from the Food and Drug Administration. For Geron, an FDA advisory panel backed its blood disorder treatment. For Madrigal, the FDA approved its treatment for a liver disease known as nonalcoholic steatohepatitis, or NASH. Yahoo Finance's Josh Lipton and Julie Hyman discuss the stocks' reaction in the video above. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich.

Yahoo Finance Video last month

GERN
+1.68%
GERNW

MDGL
Stocks to Watch Friday: Adobe, Ulta, Fisker

[**Adobe (ADBE)**](https://www.wsj.com/market-data/quotes/ADBE): The software company's latest results topped forecasts, but guidance for its current quarter [disappointed investors](https://www.wsj.com/livecoverage/stock-market-today-dow-jones-03-15-2024/card/adobe-reports-solid-earnings-but-stock-sinks-after-outlook-underwhelms-investors-fg7wmoXAIxD5cpqyO7v8).

The Wall Street Journal last month

FSR

CURYY

DSITF
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up

Geron's (GERN) pipeline candidate, imetelstat, gets FDA Committee backing for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-intermediate-1 risk myelodysplastic syndromes.

Zacks last month

002722.SZ
Geron Stock Is Soaring After Hours: What's Going On?

Geron Corp (NASDAQ:GERN) shares are soaring in Thursday's after-hours session after the company announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent anemia. What Happened: After the market close on Thursday, Geron announced that ODAC voted 12 to two in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusio

Benzinga last month

002722.SZ
Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

FOSTER CITY, Calif., March 14, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to 2 in favor of the clinical benefit/risk profile of imetelstat for the treatment of transfusion-dependent (TD) anemia in adult patients with low-to-inte

Business Wire last month

GERN
+1.68%
GERNW
UPDATE 3-Geron's blood disorder drug gets FDA advisers' backing

Advisers to the U.S. Food and Drug Administration on Thursday backed benefits of Geron's blood disorder drug, saying it outweighed the risks associated with the treatment, based on data from a late-stage trial. The panel, by a wide 12-to-2 margin, voted in favor of the benefits of the injectable drug, called imetelstat, stating the associated risks and toxicities of the treatment appear to be manageable. Geron is seeking approval to use imetelstat for treating transfusion-dependent anemia in patients with a group of blood cancers called myelodysplastic syndromes (MDS).

Reuters last month

002722.SZ
Implied Volatility Surging for Geron (GERN) Stock Options

Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.

Zacks last month

002722.SZ
UPDATE 3-US FDA staff raises concerns on Geron's blood disorder drug

The U.S. Food and Drug Administration's staff reviewers said on Tuesday they were unclear if Geron's blood disorder drug provided a clear benefit to patients in a late-stage trial and raised multiple safety concerns with the treatment. Shares of the California-based company fell 11.5% following the release of the briefing documents, ahead of a meeting of the FDA's independent advisers scheduled for Thursday. Geron is seeking approval of the injectable drug, called imetelstat, for treating transfusion-dependent anemia in patients with a group of blood cancers called myelodysplastic syndromes (MDS).

Reuters last month

002722.SZ
Geron Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Geron ( NASDAQ:GERN ) Full Year 2023 Results Key Financial Results Net loss: US$184.1m (loss widened by 30% from FY...

Simply Wall St. last month

002722.SZ
Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript

Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript February 28, 2024 Geron Corporation beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.1. GERN isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Rob and I […]

Insider Monkey last month

002722.SZ
Geron (GERN) Q4 2023 Earnings Call Transcript

GERN earnings call for the period ending December 31, 2023.

Motley Fool last month

002722.SZ
Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

FOSTER CITY, Calif., February 28, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.

Business Wire last month

GERN
+1.68%
Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

FOSTER CITY, Calif., February 14, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 financial results and business highlights before the market opens on Wednesday, February 28, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.

Business Wire 2 months ago

GERN
+1.68%
Geron to Participate in the B. Riley Securities Virtual Oncology Conference

FOSTER CITY, Calif., January 12, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, January 18th, 2024, at 10:30am ET.

Business Wire 3 months ago

GERN
+1.68%

Performance Overview

Return	GERN	S&P 500
YTD	+79.74%	+6.21%
1-Year	+42.04%	+22.56%
3-Year	+154.53%	+22.52%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Geron Corporation (GERN)

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future

Geron to Participate at Upcoming Investor Conferences in April

5 FDA decisions to watch in the second quarter

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Geron, Madrigal Pharmaceuticals jump on good news from FDA

Stocks to Watch Friday: Adobe, Ulta, Fisker

Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up

Geron Stock Is Soaring After Hours: What's Going On?

Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS

UPDATE 3-Geron's blood disorder drug gets FDA advisers' backing

Implied Volatility Surging for Geron (GERN) Stock Options

UPDATE 3-US FDA staff raises concerns on Geron's blood disorder drug

Geron Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Geron Corporation (NASDAQ:GERN) Q4 2023 Earnings Call Transcript

Geron (GERN) Q4 2023 Earnings Call Transcript

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Geron to Participate in the B. Riley Securities Virtual Oncology Conference

Performance Overview